Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer-Reference-Cited by-同舟云学术

Systematic evaluation of the efficacy‐effectiveness gap of systemic treatments in extensive disease small cell lung cancer

Published:2020-12-18 Issue:4 Volume:30 Page:445-450
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Cramer‐van der Welle Christine M.¹^ORCID,Schramel Franz M. N. H.²,Peters Bas J. M.³,Putten John W. G.⁴,Klungel Olaf H.⁵,Groen Harry J. M.⁶,Garde Ewoudt M. W.³⁵,

Affiliation:

1. Santeon Hospital Group Utrecht The Netherlands

2. Department of Pulmonary Diseases St Antonius Hospital Utrecht The Netherlands

3. Department of Clinical Pharmacy St. Antonius Hospital Utrecht The Netherlands

4. Department of Pulmonary Diseases Martini Hospital Groningen The Netherlands

5. Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences Utrecht University Utrecht The Netherlands

6. University of Groningen and University Medical Center Groningen Department of Pulmonary Diseases Groningen The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5179

Reference44 articles.

1. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Netherlands Comprehensive Cancer Organisation (IKNL).www.cijfersoverkanker.nl(Accessed March 14 2019).

3. Lung Cancer — Time to Move on from Chemotherapy

4. Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

5. Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining real-world data with randomized controlled trials results in better information oncology decision making;Real-World Data & Evidence;2022-08-08

2. Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors;Cancer Epidemiology;2022-06

3. Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life;Current Medical Research and Opinion;2022-05-31

4. 'Considering the totality of evidence: Combining real‐world data with clinical trial results to better inform decision‐making;Pharmacoepidemiology and Drug Safety;2021-03-14